Ring size of somatostatin analogues (ODT-8) modulates receptor selectivity and binding affinity

Journal of Medicinal Chemistry

Volumn 51, Issue 9, 2008, Pages 2668-2675

  Erchegyi, Judit ^a   Grace, Christy Rani R ^b   Samant, Manoj ^a   Cescato, Renzo ^c   Piccand, Veronique ^c   Riek, Roland ^b   Reubi, Jean Claude ^c   Rivier, Jean E ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; DIMETHYL SULFOXIDE; DISULFIDE; SOMATOSTATIN DERIVATIVE;

ARTICLE; ATOM; BINDING AFFINITY; DRUG SELECTIVITY; DRUG SYNTHESIS; NUCLEAR MAGNETIC RESONANCE; RECEPTOR BINDING; STEREOCHEMISTRY; STRUCTURE ANALYSIS; THREE DIMENSIONAL IMAGING;

ANIMALS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PEPTIDES, CYCLIC; RADIOLIGAND ASSAY; RECEPTORS, SOMATOSTATIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 42949169479     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701444y     Document Type: Article

References (56)

1. Brazeau, P.; Vale, W.; Burgus, R.; Ling, N.; Butcher, M.; Rivier, J.; Guillemin, R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973, 179, 77-79.
2. Guillemin, R.; Gerich, J. E. Somatostatin: Physiological and clinical significance. Annu. Rev. Med. 1976, 27, 379-388.
3. Reubi, J. C.; Schaer, J. C.; Waser, B.; Wenger, S.; Heppeler, A.; Schmitt, J. S.; Mäcke, H. R. Affinity profiles for human somatostatin receptor sst1-sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 2000, 27, 273-282.
4. Janecka, A.; Zubrzycka, M.; Janecki, T. Review: Somatostatin analogs. J. Pept. Res. 2001, 58, 91-107.
5. Schally, A. V.; Comaru-Schally, A. M.; Nagy, A.; Kovacs, M.; Szepeshazi, K.; Plonowski, A.; Varga, J. L.; Halmos, G. Hypothalamic hormones and cancer. Front. Neuroendocrinol. 2001, 22, 248-291.
6. Lamberts, S. W.; van der Lely, A. J.; Hofland, L. J. New somatostatin analogs: Will they fulfill old promises. Eur. J. Endocrinol. 2002, 146, 701-705.
7. Weckbecker, G.; Lewis, I.; Albert, R.; Schmid, H. A.; Hoyer, D.; Bruns, C. Opportunities in somatostatin research: Biological, chemical and therapeutic aspects. Nat. Rev. Drug Discovery 2003, 2, 999-1017.
8. van der Hoek, J.; Hofland, L. J.; Lamberts, S. W. Novel subtype specific and universal somatostatin analogues: Clinical potential and pitfalls. Curr. Pharm. Des. 2005, 11, 1573-1592.
9. Reubi, J. C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 2003, 24, 389-427.
10. Panteris, V.; Karamanolis, D. G. The puzzle of somatostatin: Action, receptors, analogues and therapy. Hepato-Gastroenterology 2005, 52, 1771-1781.
11. Petersenn, S. Efficacy and limits of somatostatin analogs. J. Endocrinol. Invest. 2005, 28, 53-57.
12. Tulipano, G.; Schulz, S. Novel insights in somatostatin receptor physiology. Eur. J. Endocrinol. 2007, 156, S3-S11.
13. Reisine, T.; Bell, G. I. Molecular biology of somatostatin receptors. Endocr. Rev. 1995, 16, 427-442.
14. Csaba, Z.; Dournaud, P. Cellular biology of somatostatin receptors. Neuropeptides 2001, 35, 1-23.
15. Moller, L. N.; Stidsen, C. E.; Hartmann, B.; Holst, J. J. Somatostatin receptors. Biochim. Biophys. Acta 2003, 1616, 1-84.
16. Olias, G.; Viollet, C.; Kusserow, H.; Epelbaum, J.; Meyerhof, W. Regulation and function of somatostatin receptors. J. Neurochem. 2004, 89, 1057-1091.
17. Reubi, J. C.; Waser, B.; Liu, Q.; Laissue, J. A.; Schonbrunn, A. Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: Membranous versus intracellular location. J. Clin. Endocrinol. Metab. 2000, 85, 3882-3891.
18. Lewis, I.; Bauer, W.; Albert, R.; Chandramouli, N.; Pless, J.; Weckbecker, G.; Bruns, C. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J. Med. Chem. 2003, 46, 2334-2344.
19. Reubi, J. C.; Waser, B.; Schaer, J.-C.; Laissue, J. A. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 2001, 28, 836-846.
20. Reubi, J. C.; Macke, H. R.; Krenning, E. P. Candidates for peptide receptor radiotherapy today and in the future. J. Nucl. Med. 2005, 46, 67S-75S.
21. Eberle, A. N.; Mild, G.; Froidevaux, S. Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: Applications to somatostatin receptor-expressing tumors. J. Recept. Signal Transduction Res. 2004, 24, 319-455.
22. Vale, W.; Rivier, C.; Brown, M.; Rivier, J. Pharmacology of TRF, LRF and somatostatin. Hypothalamic Peptide Hormones and Pituitary Regulation: Advances in Experimental Medicine and Biology; Plenum Press: New York, 1977; pp 123-156.
23. Vale, W.; Rivier, J.; Ling, N.; Brown, M. Biologic and immunologic activities and applications of somatostatin analogs. Metabolism 1978, 27, 1391-1401.
24. 4-selective somatostatin (SRIF) agonists. Part I: Lead identification using a betide scan. J. Med. Chem. 2003, 46, 5579-5586.
25. Chen, L.; Hoeger, C.; Rivier, J.; Fitzpatrick, V. D.; Vandlen, R. L.; Tashjian, A. H., Jr. Structural basis for the binding specificity of a SSTR1-selective analog of somatostatin. Biochem. Biophys. Res. Commun. 1999, 258, 689-694.
26. Rivier, J. E.; Hoeger, C.; Erchegyi, J.; Gulyas, J.; DeBoard, R.; Craig, A. G.; Koerber, S. C.; Wenger, S.; Waser, B.; Schaer, J.-C.; Reubi, J. C. Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1). J. Med. Chem. 2001, 44, 2238-2246.
27. Rivier, J. E.; Kirby, D. A.; Erchegyi, J.; Waser, B.; Eltschinger, V.; Cescato, R.; Reubi, J. C. Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J. Med. Chem. 2005, 48, 515-522.
28. Erchegyi, J.; Hoeger, C. A.; Low, W.; Hoyer, D.; Waser, B.; Eltschinger, V.; Schaer, J.-C.; Cescato, R.; Reubi, J. C.; Rivier, J. E. Somatostatin receptor 1 selective analogues: 2. N-methylated scan. J. Med. Chem. 2005, 48, 507-514.
29. Grace, C. R. R.; Durrer, L.; Koerber, S. C.; Erchegyi, J.; Reubi, J. C.; Rivier, J. E.; Riek, R. Somatostatin receptor 1 selective analogues: 4. Three-dimensional consensus structure by NMR. J. Med. Chem. 2005, 48, 523-533.
30. Reubi, J. C.; Schaer, J.-C.; Wenger, S.; Hoeger, C.; Erchegyi, J.; Waser, B.; Rivier, J. SST3-selective potent peptidic somatostatin receptor antagonists. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 13973-13978.
31. Gairi, M.; Saiz, P.; Madurga, S.; Roig, X.; Erchegyi, J.; Koerber, S. C.; Reubi, J. C.; Rivier, J. E.; Giralt, E. Conformational analysis of a potent SSTR3-selective somatostatin analogue by NMR in water solution. J. Pept. Sci. 2006, 12, 82-91.
32. 4-selective somatostatin (SRIF) agonists. Part II: Analogues with β-methyl-3-(2-naphthyl)-alanine substitutions at position 8. J. Med. Chem. 2003, 46, 5587-5596.
33. 4-selective somatostatin (SRIF) agonists. Part III: Analogues amenable to radiolabeling. J. Med. Chem. 2003, 46, 5597-5605.
34. 4-selective somatostatin (SRIF) agonists. Part IV: Three-dimensional consensus structure by NMR. J. Med. Chem. 2003, 46, 5606-5618.
35. Samant, M. P.; Rivier, J. E. Norcystine, a new tool for the study of the structure-activity relationship of peptides. Org. Lett. 2006, 8, 2361-2364.
36. Armstrong, M. D.; Lewis, J. D. Thioether derivatives of cysteine and homocysteine. J. Org. Chem. 1950, 16, 749-753.
37. Ambler, R. P. Methods in Enzymology; Academic Press: New York, 1967; p 437.
38. Miller, C.; Rivier, J. Peptide chemistry: Development of high-performance liquid chromatography and capillary zone electrophoresis. Biopolym. Pept. Sci. 1996, 40, 265-317.
39. Miller, C.; Rivier, J. Analysis of synthetic peptides by capillary zone electrophoresis in organic/aqueous buffers. J. Pept. Res. 1998, 51, 444-451.
40. Reubi, J. C.; Schaer, J. C.; Waser, B.; Hoeger, C.; Rivier, J. A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors. Eur. J. Pharmacol. 1998, 345, 103-110.
41. 2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J. Med. Chem. 2006, 49, 4487-4496.
42. Güntert, P.; Mumenthaler, C.; Wüthrich, K. Torsion angle dynamics for NMR structure calculation with the new program DYANA. J. Mol. Biol. 1997, 273, 283-298.
43. Hagler, A. T.; Dauber, P.; Osguthorpe, D. J.; Hempel, J. C. Dynamics and conformational energetics of a peptide hormone: Vasopressin. Science 1985, 227, 1309-1315.
44. Melacini, G.; Zhu, Q.; Osapay, G.; Goodman, M. A refined model for the somatostatin pharmacophore: Conformational analysis of lanthionine-sandostatin analogs. J. Med. Chem. 1997, 40, 2252-2258.
45. Erchegyi, J.; Hoeger, C.; Wenger, S.; Waser, B.; Schaer, J.-C.; Reubi, J. C.; Rivier, J. E. N-methyl scan of a sst1-selective somatostatin (SRIF) analog. In Peptides -The wave of the future: 2nd International Peptide Symposium/17th American Peptide Symposium; American Peptide Symposium: San Diego, CA, 2001; pp 719-720.
46. Liapakis, G.; Fitzpatrick, D.; Hoeger, C.; Rivier, J.; Vandlen, R.; Reisine, T. Identification of ligand binding determinants in the somatostatin receptor subtypes mSSTR1 and mSSTR2. J. Biol. Chem. 1996, 271, 20331-20339.
47. Melacini, G.; Zhu, Q.; Goodman, M. Multiconformational NMR analysis of sandostatin (octreotide): Equilibrium between β-sheet and partially helical structures. Biochemistry 1997, 36, 1233-1241.
48. Osapay, G.; Prokai, L.; Kin, H.-S.; Medzihradszky, K. F.; Coy, D. H.; Liapakis, G.; Reisine, T.; Melacini, G.; Zhu, Q.; Wang, S. H.-H.; Mattern, R.-H.; Goodman, M. Lanthionine-somatostatin analogs: Synthesis, characterization, biological activity, and enzymatic stability studies. J. Med. Chem. 1997, 40, 2241-2251.
49. Grace, C. R. R.; Perrin, M.; DiGruccio, M.; Miller, C.; Rivier, J.; Vale, W.; Riek, R. NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G-protein coupled receptor. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 12836-12841.
50. Grace, C. R. R.; Perrin, M.; Gulyas, J.; DiGruccio, M.; Cantle, J. P.; Rivier, J.; Vale, W.; Riek, R. Structure of the N-terminal domain of a type B1 G-protein coupled receptor in complex with a peptide ligand. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 4858-4863.
51. Grace, C. R. R.; Cervini, L.; Gulyas, J.; Rivier, J.; Riek, R. Astressinamide and astressin-acid are structurally different in DMSO. Biopolymers 2007, 87, 196-205.
52. Wüthrich, K. NMR of Proteins and Nucleic Acids; J. Wiley & Sons: New York, 1986.
53. Maple, J. R.; Thacher, T. S.; Dinur, U.; Hagler, A. T. Biosym force field research results in new techniques for the extraction of inter-and intramolecular forces. Chem. Des. Auto. News 1990, 5, 5-10.
54. Koerber, S. C.; Rizo, J.; Struthers, R. S.; Rivier, J. E. Consensus bioactive conformation of cyclic GnRH antagonists defined by NMR and molecular modeling. J. Med. Chem. 2000, 43, 819-828.
55. Hagler, A. T. Theoretical simulation of conformation, energetics and dynamics of peptides. The Peptides: Analysis, Synthesis, Biology; Academic Press: Orlando, FL, 1985; pp 213-299.
56. Koradi, R.; Billeter, M. MOLMOL: A program for display and analysis of macromolecular structures. PDB Newsletter 1998, 84, 5-7.